Norah Terrault

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation
    Norah A Terrault
    University of California San Francisco, San Francisco, CA 64153, USA
    Liver Transpl 9:S95-S100. 2003
  2. ncbi request reprint Treatment of recurrent hepatitis B infection in liver transplant recipients
    Norah A Terrault
    University of California, San Francisco, CA 64143 0538, USA
    Liver Transpl 8:S74-81. 2002
  3. ncbi request reprint Sexual activity as a risk factor for hepatitis C
    Norah A Terrault
    Gastroenterology Division, Department of Medicine, University of California, San Francisco, CA 94143, USA
    Hepatology 36:S99-105. 2002
  4. ncbi request reprint Motion - the available treatments for hepatitis C are cost effective: arguments for the motion
    Norah Terrault
    Department of Medicine, University of California, San Francisco 94143 0538, USA
    Can J Gastroenterol 16:705-9. 2002
  5. ncbi request reprint Hepatitis B immune globulin preparations and use in liver transplantation
    Norah A Terrault
    Department of Medicine, University of California, 513 Parnassus Avenue, Room S 537, San Francisco, CA 94143 0538, USA
    Clin Liver Dis 7:537-50. 2003
  6. pmc Acute hepatitis C in an HIV-infected patient: a case report and review of literature
    Todd H Driver
    School of Medicine, University of California, San Francisco, San Francisco, CA, USA
    J Gen Intern Med 28:734-8. 2013
  7. doi request reprint Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis
    Francis Y Yao
    Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
    Hepatology 48:819-27. 2008
  8. ncbi request reprint Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective
    Norah Terrault
    University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 11:716-32. 2005
  9. pmc Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era
    Carl L Berg
    Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    Hepatology 54:1313-21. 2011
  10. doi request reprint Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies
    Varun Saxena
    University of California, San Francisco, California, San Francisco, USA
    Curr Opin Organ Transplant 17:216-24. 2012

Detail Information

Publications51

  1. ncbi request reprint Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation
    Norah A Terrault
    University of California San Francisco, San Francisco, CA 64153, USA
    Liver Transpl 9:S95-S100. 2003
    ..4. It is unclear whether the preemptive antiviral treatment is superior to delaying treatment until recurrent disease is present and controlled trials addressing this issue are needed...
  2. ncbi request reprint Treatment of recurrent hepatitis B infection in liver transplant recipients
    Norah A Terrault
    University of California, San Francisco, CA 64143 0538, USA
    Liver Transpl 8:S74-81. 2002
    ..6. Antiviral therapy with two or more suitable agents may minimize the chance for viral resistance; therefore, future therapeutic strategies likely will use combination therapy in the long-term management of recurrent HBV disease...
  3. ncbi request reprint Sexual activity as a risk factor for hepatitis C
    Norah A Terrault
    Gastroenterology Division, Department of Medicine, University of California, San Francisco, CA 94143, USA
    Hepatology 36:S99-105. 2002
    ..Current recommendations about sexual practices are different for persons with chronic HCV infection who are in steady monogamous partnerships versus those with multiple partners or who are in short-term sexual relationships...
  4. ncbi request reprint Motion - the available treatments for hepatitis C are cost effective: arguments for the motion
    Norah Terrault
    Department of Medicine, University of California, San Francisco 94143 0538, USA
    Can J Gastroenterol 16:705-9. 2002
    ..CEAs can facilitate this process by determining which treatment strategies are likely to yield the greatest clinical benefits without excessive expenditures...
  5. ncbi request reprint Hepatitis B immune globulin preparations and use in liver transplantation
    Norah A Terrault
    Department of Medicine, University of California, 513 Parnassus Avenue, Room S 537, San Francisco, CA 94143 0538, USA
    Clin Liver Dis 7:537-50. 2003
    ..Thus, there remains a need to develop and test new forms of anti-HBs therapy, so that effective but less expensive forms of immunoprophylaxis can be made available...
  6. pmc Acute hepatitis C in an HIV-infected patient: a case report and review of literature
    Todd H Driver
    School of Medicine, University of California, San Francisco, San Francisco, CA, USA
    J Gen Intern Med 28:734-8. 2013
    ....
  7. doi request reprint Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis
    Francis Y Yao
    Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
    Hepatology 48:819-27. 2008
    ..2% and 92.1%, respectively. No patient had HCC recurrence after a median posttransplantation follow-up of 25 months. The only factor predicting treatment failure was pretreatment alpha-fetoprotein >1,000 ng/mL...
  8. ncbi request reprint Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective
    Norah Terrault
    University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 11:716-32. 2005
  9. pmc Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era
    Carl L Berg
    Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    Hepatology 54:1313-21. 2011
    ..39; P = 0.0003) and MELD ≥ 15 (HR = 0.42; P = 0.0006). Among candidates with HCC, a benefit of LDLT was not seen for MELD <15 (HR = 0.82, P = 0.65) but was seen for MELD ≥ 15 (HR = 0.29, P = 0.043)...
  10. doi request reprint Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies
    Varun Saxena
    University of California, San Francisco, California, San Francisco, USA
    Curr Opin Organ Transplant 17:216-24. 2012
    ....
  11. pmc De novo malignancies following liver transplantation: a case-control study with long-term follow-up
    Francis Y Yao
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0538, USA
    Clin Transplant 20:617-23. 2006
    ..Long-term survival data on de novo malignancy are limited following orthotopic liver transplantation (OLT) when compared with controls without malignancies...
  12. pmc Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C
    Norah A Terrault
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0538, USA
    Clin Gastroenterol Hepatol 6:1403-11. 2008
    ..Prior studies suggest the rate of liver fibrosis progression is slower in African Americans (AAs) than Caucasian Americans (CAs) with chronic HCV infection...
  13. pmc Transplant tourism to China: the impact on domestic patient-care decisions
    Scott W Biggins
    Gastroenterology Heath Outcomes Policy and Economics Research Program, University of California San Francisco, San Francisco, CA 94143 0538, USA
    Clin Transplant 23:831-8. 2009
    ..001). Conclusions: Transplant professionals expressed concern about organ procurement practices in China which influenced their patient-care decision-making...
  14. doi request reprint Multidisciplinary management of hepatocellular carcinoma
    Jennifer Guy
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Clin Gastroenterol Hepatol 10:354-62. 2012
    ..We present each specialist's viewpoint on controversies and advances in the management of hepatocellular carcinoma...
  15. ncbi request reprint Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores
    Francis Y Yao
    Department of Medicine University of California, San Francisco, San Francisco, CA, USA
    Hepatology 39:230-8. 2004
    ..In conclusion, our results suggest that severity of graft failure based on CTP and MELD scores may be associated with worse outcome after re-OLT and provide a cautionary note for the "sickest first" policy of organ allocation...
  16. ncbi request reprint Hepatitis C virus and lichen planus: a review
    Nita Chainani-Wu
    Department of Stomatology, Division of Oral Medicine, Oral Pathology, and Oral Radiology, University of California, San Francisco, CA 94143 0658, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:171-83. 2004
    ..It is important to determine whether there is an association between OLP and HCV infection so that guidelines regarding the routine HCV testing of patients with OLP can be developed for clinicians...
  17. ncbi request reprint A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents
    K Arnold Chan
    Department of Medicine, Brigham and Women s Hospital, Boston, Mass, USA
    Arch Intern Med 163:728-34. 2003
    ..The incidence of acute liver failure or serious liver injury in diabetic patients is needed to evaluate the safety of hypoglycemic drug therapy...
  18. ncbi request reprint Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
    Hari S Conjeevaram
    Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 131:470-7. 2006
    ..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy...
  19. ncbi request reprint Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity
    Eithan Galun
    Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel
    J Hepatol 46:37-44. 2007
    ..A Phase 1 clinical trial was designed to test safety, tolerability, and antiviral activity of HCV-AB68 in patients with chronic HCV-infection...
  20. ncbi request reprint The changing epidemiology and natural history of hepatitis C virus infection
    Stephanie R Bialek
    Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Clin Liver Dis 10:697-715. 2006
    ..Emerging risk factors for disease progression include steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics...
  21. pmc Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  22. ncbi request reprint Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?
    Alexander Kuo
    J Hepatol 46:359-61. 2007
  23. ncbi request reprint Management of hepatitis B in liver transplant recipients
    Carla S Coffin
    Department of Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
    J Viral Hepat 14:37-44. 2007
    ..There is an increasing need for individualization of therapy based on prior drug exposures, level of HBV DNA at time of transplantation and type of prophylaxis used...
  24. pmc Influence of cannabis use on severity of hepatitis C disease
    Julie H Ishida
    Department of Medicine, University of California at San Francisco, San Francisco, California, USA
    Clin Gastroenterol Hepatol 6:69-75. 2008
    ..Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial...
  25. doi request reprint Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection
    Florian Bihl
    Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland
    Liver Transpl 14:478-85. 2008
    ..Thus, the profile of the cellular immunity against HBV was in immune suppressed patients similar to subjects with chronic HBV infection with suppressed HBV-DNA...
  26. pmc Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection
    Charles D Howell
    University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
    Clin Gastroenterol Hepatol 6:575-83. 2008
    ....
  27. ncbi request reprint Should HCV-related cirrhosis be a contraindication for retransplantation?
    Scott W Biggins
    Liver Transpl 9:236-8. 2003
  28. ncbi request reprint The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California, USA
    Clin J Am Soc Nephrol 2:563-75. 2007
    ..New antiviral agents that can be used in dialysis patients (e.g., ribavirin alternatives) and in the posttransplantation setting (e.g., IFN alternatives) are needed to improve outcomes in these populations...
  29. ncbi request reprint Treating hepatitis C infection in liver transplant recipients
    Norah A Terrault
    Department of Medicine Gastroenterology, University of California San Francisco, San Francisco, CA, USA
    Liver Transpl 12:1192-204. 2006
    ..Liver Transpl 12:1192-1204, 2006. (c) 2006 AASLD...
  30. ncbi request reprint Evidence-based incorporation of serum sodium concentration into MELD
    Scott W Biggins
    University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1652-60. 2006
    ..Serum sodium (Na) concentrations have been suggested as a useful predictor of mortality in patients with end-stage liver disease awaiting liver transplantation...
  31. ncbi request reprint Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation
    Norah A Terrault
    Department of Medicine, University of California at San Francisco, San Francisco, CA 64143 0538, USA
    Liver Transpl 12:801-7. 2006
    ..In HIV-HBV coinfected patients undergoing LT, HBV recurrence is successfully prevented with combination prophylaxis using HBIG and antivirals...
  32. ncbi request reprint Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation
    Ryan A McTaggart
    Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA 94143 0780, USA
    Liver Transpl 10:975-85. 2004
    ..Alternatively, the association of HCV and EAR may result from an increased frequency of allograft biopsy and may be further exacerbated by inability to accurately diagnose EAR in the setting of recurrent HCV...
  33. ncbi request reprint Antiviral therapy in patients with chronic hepatitis B and cirrhosis
    Cindy J Lai
    Division of General Internal Medicine, University of California San Francisco, S357, 513 Parnassus Avenue, San Francisco, CA 94143 0538, USA
    Gastroenterol Clin North Am 33:629-54, x-xi. 2004
    ..The newest oral nucleotide analog, adefovir dipivoxil, has shown excellent efficacy in treatment-naïve and lamivudine-resistant HBV patients and has lower rates of resistance in the short-term...
  34. ncbi request reprint Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection
    Audrey L French
    CORE Center Cook County Hospital, Rush Medical College, Chicago, IL 60612, USA
    Clin Infect Dis 39:402-10. 2004
    ..65% to increases of 7.57% of the ULN per year; P values of.19-.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection...
  35. ncbi request reprint New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection
    Mandana Khalili
    Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA
    Liver Transpl 10:349-55. 2004
    ..However, among those developing de novo persistent diabetes, HCV is one of the most important risk factors. This adds further support to the epidemiological data linking HCV and diabetes...
  36. pmc Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)
    Tarek Elbeik
    Department of Laboratory Medicine, University of California, San Francisco 94110, USA
    J Clin Microbiol 42:563-9. 2004
    ..1%), a fold change of 2.6. Thus, the observed fold change between any two consecutive HCV RNA measures is expected to be less than 2.6-fold (equivalent to 0.41 log(10) IU/ml) 95% of the time in clinically stable individuals...
  37. ncbi request reprint Kidney and liver transplantation in HIV-infected patients: case presentations and review
    Michelle E Roland
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    AIDS Patient Care STDS 17:501-7. 2003
    ....
  38. ncbi request reprint Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study
    Peter G Stock
    Department of Surgery, Division of Transplantation, University of California, San Francisco, California 94143 0780, USA
    Transplantation 76:370-5. 2003
    ....
  39. ncbi request reprint Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation
    Sandy Feng
    Department of Surgery, Division of Transplantation, University of California, San Francisco, San Francisco, CA 94143 0780, USA
    Transplantation 74:1657-63. 2002
  40. ncbi request reprint Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation
    Amandeep K Shergill
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 5:118-24. 2005
    ..Future studies should focus on alternative dosing schedules with more aggressive use of adjuvant therapies, including GFs...
  41. ncbi request reprint Alcohol use and hepatitis C
    Marion G Peters
    Department of Gastroenterology, University of California, San Francisco, CA 94143, USA
    Hepatology 36:S220-5. 2002
    ..The literature is inadequate to provide definitive recommendations regarding the effect of light to moderate alcohol use in patients with hepatitis C...
  42. ncbi request reprint Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years
    Mandana Khalili
    Department of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Transplant 20:1-9. 2006
    ..We conclude that there is considerable variability in the management of HCV among transplant programs and over time...
  43. ncbi request reprint Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease
    Rolland C Dickson
    Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Jacksonville, FL 32216, USA
    Liver Transpl 12:124-33. 2006
    ..In conclusion, this study provides a rationale for the use of lower HBIg doses in HBV patients with suppressed replication undergoing LT...
  44. ncbi request reprint Treatment of recurrent hepatitis C in liver transplant recipients
    Norah A Terrault
    Division of Gastroenterology, University of California at San Francisco, San Francisco, CA 94143 0538, USA
    Clin Gastroenterol Hepatol 3:S125-31. 2005
    ..Overall, the treatment of HCV disease in transplant recipients leaves much to be desired and there is an urgent need of new HCV therapies in this patient population...
  45. ncbi request reprint Treatment of recurrent hepatitis C after liver transplantation
    Scott W Biggins
    Division of Gastroenterology, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, S357, Box 0538 San Francisco, CA 94143, USA
    Clin Liver Dis 9:505-23, ix. 2005
    ..Prophylactic and preemptive therapies, as well as treatment of established recurrent disease, are the strategies reviewed...
  46. ncbi request reprint Serum sodium predicts mortality in patients listed for liver transplantation
    Scott W Biggins
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Hepatology 41:32-9. 2005
    ..Addition of serum sodium to MELD increases the ability to predict 3- and 6-month mortality in patients with cirrhosis...
  47. ncbi request reprint Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis
    Derek Patel
    Division of Gastroenterology, Department of Medicine, University of California, 513 Parnassus Avenue, San Francisco, CA 94143 0538, USA
    Clin Gastroenterol Hepatol 3:75-84. 2005
    ..Surveillance might detect HCC at a treatable stage. We estimated the clinical and economic consequences of a common HCC surveillance strategy in patients with HCV-related cirrhosis in the context of alternative HCC treatment strategies...
  48. ncbi request reprint Sex and hepatitis C
    Norah A Terrault
    Am J Gastroenterol 100:825-6. 2005
  49. ncbi request reprint Burden of liver disease in the United States: summary of a workshop
    W Ray Kim
    Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hepatology 36:227-42. 2002
  50. pmc Outcomes of donor evaluation in adult-to-adult living donor liver transplantation
    James F Trotter
    Department of Surgery, University of Colorado, Denver, CO, USA
    Hepatology 46:1476-84. 2007
    ..Other predictors of donor acceptance included earlier year of evaluation and transplant center...
  51. ncbi request reprint Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy
    Norah A Terrault
    Division of Gastroenterology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Semin Liver Dis 27:18-24. 2007
    ....